Paris-based biotech startup EG 427 has successfully closed a €27 million Series B financing round to further develop pinpoint genetic medicines for chronic neurological diseases. The round was co-led by Andera Partners and Bpifrance as part of the InnoBio investment strategy, with participation from SCI Ventures and existing investors. MTS Health Partners served as the exclusive financial advisor.

“The successful closing of this financing is a major milestone for EG 427,” said Philippe Chambon, MD, PhD, CEO of EG 427. “Our focus is on neuro-urology, a field that remains underserved despite its significant impact on healthcare systems. With this funding, we can advance our first clinical program targeting neurogenic bladder (NDO), a condition with limited treatment options.”

Founded in 2019, EG 427 specializes in non-replicating HSV-1 (nrHSV-1) vector technology to treat sensory neuron-based diseases. Its lead product, EG110A, is designed to selectively silence overactive bladder sensory neurons while preserving normal voiding function. This genetic medicine targets severe bladder conditions such as neurogenic detrusor overactivity (NDO) and overactive bladder (OAB), which often affect patients with spinal cord injury (SCI), multiple sclerosis, and Parkinson’s disease.

The company’s HERpes Modular Expression System (HERMES) platform enables highly targeted neurotherapeutics with precise transgene expression in specific neuron subsets. EG 427 highlights the advantages of nrHSV-1 vectors, which allow for repeatable dosing and cost-effective production compared to AAV-based gene therapies.

The Series B funding will support the Phase 1b/2a clinical trial of EG110A for NDO in SCI patients, a U.S.-based study that could pave the way for broader applications in neuro-urology. Additionally, the investment will help expand EG 427’s pipeline with new therapeutic vectors leveraging its HERMES technology.

“As a leader in non-replicating HSV vector development, EG 427 has the potential to revolutionize genetic medicine with highly targeted delivery,” said Benoît Barteau, Investment Director at Bpifrance – InnoBio funds. Raphaël Wisniewski, Partner at Andera Partners, added, “EG110A could bring significant improvements to neuro-urology treatments, and we’re excited to support EG 427’s continued innovation.”

With its cutting-edge genetic medicine platform, EG 427 aims to provide long-term, cost-effective solutions for chronic neurological diseases, addressing unmet medical needs in neuro-urology and beyond.